Member Info for oogleflugal

Techtonic. The last line of the presentation RNS ‘the will be no new news disclosed at Sharesoc presentation.’

The one thing Mr Charisma has managed to do recently is amass an impressive collection of advisors and consultants. The problem for many is the excessive constant dilution and billions of warrants exercisable by the largest new share holder Mr Wardle a specialist investor in crisis situations and of course fees for the last two placings taken in warrants by the broker. I can’t see there not being another placing before we see any meaningful revenue if we are still two years away from clinical trials. Mr Charisma likes to compare with American companies which is meaningless and misguided.

Not only that Glow, the market seems to be making light of the fact that Isn’t clearly states that the new revelations will have an adverse effect on the company. No kidding. Big take the rap and Murray has hidden the dosh away in family trust in off shore funds. Sounds very well planned

Looks like Ian Johnson is doing all the work for the fraud squad

The case against Murray looks stronger but in the short term this will impact the company. Can only hope mediation works.

Actually Trinity were already holders . This was a 166,00 top up which took them over 5 percent threshold

It’s not just Magnetica! They are still waiting for share of ‘imminent’ £900 million government contract for Meatalcrafts steel nuclear waste containers and Luton land sale. All potential value creations. Interesting to See a new institution Trinity Bridge London take a 5 percent stake last week and no affect on the share price. Maybe mopping up sellers? Remembering the terrible state the government have dug the uk into I think they are doing remarkably well.

Any tiny bit of good news and the SP drops. It’s called the Reeves effect

Tariffs have instigated talks of starting uk production line. Horse probably bolted on that one . By the time they do that Trump and tariffs will be a distant memory hopefully

Good review on Vox with Amati’s Paul Jourdon last week. Uk rail , civil servants the usual fly in ointment and debt put me off in the end . Will monitor closely.

Any small cap Berenberg target take with a huge sack of salt from previous experience.

Poor management not to warn on guidance pre interims. That’s why it’s been such a savage reaction . It’s still profitable FFs. It’s about the fourth time I’ve nearly bought in , but they just keep putting me off. Catching falling knives is disastrous. Need to see some evidence that they have a grip on this

Another presentation wasting valuable resources . Our money. No new material . Just a rehash of a rehash.

Fascinating post Bobby. They are two quite different tests although both for post op analysis treatment management. Curiously they both received FDA approval within months of each other. Tutivia is looking for early post op rejection where as Ibox monitors longer term graft survival a year after transplant. So not really competing or necessarily obvious partners. Tutivia is particularly important in making sure a patient receives the right treatment some medicines are particularly toxic and unsuitable. It not a case of one size fits all. Fantastic to see such advances in making transplants more successful and survivable.

Don’t think you will miss anything here. Be at least two years before Nigel wakes up from his afternoon nap

A lot of noise about oil price being stuck in a low range for years, but actually production is expected to rise. Anything that can help mitigate production cost and increase safety is likely to be a winner. Plexus improved tech well heads are such a case. Surprised they are not ordering more.. Think there is an option to further license agreements which would be less outlay and risk . Looking forward to update

Presentation of interims on IMC next Tuesday. After a solid July update further rise in margins and cash generation. Still unlikely to see restatement of dividends. Wouldn’t mind so much if that was countered by real progress in the Enzyme investment. A lot more positive market reaction than there has been as evidence of turnaround continues.

And of course hiring the legendary ex Niox/ex Bioquel boss Ian Johnson is a master stroke. No one better suited to this situation

Amati manager asks the question ‘why did the government buy the wrong tags from the wrong company G4?’ Why indeed? Doesn’t our government always do dodgy deals with dodgy companies wasting tax payers money. Investigation needed there. Fortunately like many great uk companies they do great business abroad in Australasia and now into America. Their tags are more robust and can even detect alcohol abuse. Out of court settlement seems likely which the former CEO will have to pay anyway providing they can find the money. Phenomenal potential here

The tax appeal against 9.2 million dollars has been denied but they are looking at getting penalties waived. Yet to be assessed. Quite a mixed bag. Outlook for oil price is stagnating between 50-80 dollars for a few years, barring geopolitical shocks and they certainly can’t be ruled out. Anyway demand and production are likely to increase. I suspect ramped up production in shale is pressuring oil price. Must be a reaction to eps and profit drop which as mentioned looks to be a one off. Also continuing to not make a definitive statement on shareholder reward doesn’t help sentiment

Offeree reserves right to reduce offer in event of any pending dividend doesn’t sound overly encouraging. Can only guess business still deteriorating. They spent a shed load modernising the business and it appears that business has evaporated. Pretty strange